EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axis
Cell Reports · 2024
DOI: 10.1016/j.celrep.2024.113714 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Qiuyue Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Drug resistance is the leading problem in non-small-cell lung cancer (NSCLC) therapy. The contribution of histone methylation in mediating malignant phenotypes of NSCLC is well known. However, the role of histone methylation in NSCLC drug-resistance mechanisms remains unclear. Here, our data show that EZH2 and G9a, two histone methyltransferases, are involved in the drug resistance of NSCLC. Gene manipulation results indicate that the combination of EZH2 and G9a promotes tumor growth and mediates drug resistance in a complementary manner. Importantly, clinical study demonstrates that co-expression of both enzymes predicts a poor outcome in patients with NSCLC. Mechanistically, G9a and EZH2 interact and promote the silencing of the tumor-suppressor gene SMAD4, activating the ERK/c-Myc signaling pathway. Finally, SU08, a compound targeting both EZH2 and G9a, is demonstrated to sensitize resistant cells to therapeutic drugs by regulating the SMAD4/ERK/c-Myc signaling axis. These findings uncover the resistance mechanism and a strategy for reversing NSCLC drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Department of Biochemistry and Molecular Biology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Department of Pathology, General Hospital of Central Theater Command of People's Liberation Army, Wuhan 430070, China.
- Biobank Center, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
- Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: spucgl@163.com.
Zitieren
APA
Zhang, Q., Shi, Y., Liu, S., Yang, W., Chen, H., Guo, N., Sun, W., Zhao, Y., Ren, Y., Ren, Y., Jia, L., Yang, J., Yun, Y., Chen, G., Wang, L., & Wu, C. (2024). EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axis. Cell Reports. https://doi.org/10.1016/j.celrep.2024.113714
Vancouver
Zhang Q, Shi Y, Liu S, Yang W, Chen H, Guo N, et al. EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axis. Cell Reports. 2024. doi:10.1016/j.celrep.2024.113714
BibTeX
@article{Zhang2024,
author = {Zhang, Qiuyue and Shi, Yajie and Liu, Sen and Yang, Weiming and Chen, Huiping and Guo, Ning and Sun, Wanyu and Zhao, Yongshan and Ren, Yuxiang and Ren, Yong and Jia, Lina and Yang, Jingyu and Yun, Yi and Chen, Guoliang and Wang, Lihui and Wu, Chunfu},
title = {EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axis},
journal = {Cell Reports},
year = {2024},
doi = {10.1016/j.celrep.2024.113714}
}
EUVIMED